$APLD

Applied Digital Corp.

9
2
0

No SEC Form 4 filings for $APLD in the last 30 days.

See all $APLD insider activity →
Med

Applied Digital (APLD) Draws UBS Attention, Is The Stock Cheap Or Pricey?

UBS initiated coverage on Applied Digital (APLD), highlighting its AI data center operations. The stock has seen volatility, with a 30.9% drop over 90 days but a 19.8% gain over 1 year. Bulls see growth potential, while bears point to debt and customer concentration. The company secured a $7B, 15-year lease with CoreWeave, supporting future revenue. Analysts debate its valuation, with a fair value estimate of $68.35 vs. a last close of $27.06.

Applied Digital vs. IREN: Which Technology Stock Is a Better Buy in 2026?

Applied Digital (APLD) and IREN (IREN) are transitioning from crypto to AI infrastructure. APLD reported $611.3M revenue, -$244M net loss, and a 4.0x current ratio. IREN reported $707M revenue, -$702.6M net loss, and a 3.6x current ratio. IREN secured contracts with Microsoft (MSFT) and Nvidia (NVDA). Both face risks but IREN's customer base is seen as a stronger foundation.

APLD sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 11 news stories mentioning APLD (Applied Digital Corp.). Coverage has skewed bullish: 9 bullish, 2 neutral, and 0 bearish.

Recent APLD coverage spans financial news, sector analysis and technology.

What's driving APLD

AlphAI scores every news story that mentions APLD with an AI model for sentiment and relevance, and aggregates insider trades from Applied Digital Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $APLD

Score
$APLDMedAI 8/10

Applied Digital (APLD) Draws UBS Attention, Is The Stock Cheap Or Pricey?

UBS initiated coverage on Applied Digital (APLD), highlighting its AI data center operations. The stock has seen volatility, with a 30.9% drop over 90 days but a 19.8% gain over 1 year. Bulls see growth potential, while bears point to debt and customer concentration. The company secured a $7B, 15-year lease with CoreWeave, supporting future revenue. Analysts debate its valuation, with a fair value estimate of $68.35 vs. a last close of $27.06.

$APLDMedAI 8/10

Applied Digital vs. IREN: Which Technology Stock Is a Better Buy in 2026?

Applied Digital (APLD) and IREN (IREN) are transitioning from crypto to AI infrastructure. APLD reported $611.3M revenue, -$244M net loss, and a 4.0x current ratio. IREN reported $707M revenue, -$702.6M net loss, and a 3.6x current ratio. IREN secured contracts with Microsoft (MSFT) and Nvidia (NVDA). Both face risks but IREN's customer base is seen as a stronger foundation.

UBS turns bullish on five AI data center stocks

UBS initiated coverage on five AI data center colocation stocks with Buy ratings, citing rapid growth potential due to constrained compute supply and favorable power access. The stocks are Hut 8 Mining Corp (HUT), TeraWulf (WULF), Applied Digital (APLD), Core Scientific (CORZ), and Cipher Digital (CIFR). UBS estimates the group has secured 5GW of leased capacity, worth $125 billion, with an additional 12GW in the pipeline.

$CORZMed

Hut 8, TeraWulf, Applied Digital: UBS Sees at Least 30% Upside - Applied Digital (NASDAQ:APLD), Hut 8 (NA

UBS initiated coverage of five AI data center operators with Buy ratings, citing strong lease signings and tenant quality. The firms include Core Scientific (CORZ), Cipher Mining (CIFR), Applied Digital (APLD), TeraWulf (WULF), and Hut 8 (HUT). UBS estimates significant upside, with TeraWulf leading at 40% and Applied Digital at 33%. Key catalysts include new leases, tenant shifts, and potential REIT conversion.

Microsoft upgraded, HubSpot initiated: Wall Street's top analyst calls

Stifel upgraded Microsoft (MSFT) to Buy with a $575 price target, citing sustained revenue growth. Susquehanna upgraded RXO Inc. (RXO) to Neutral with a $19 target. JPMorgan upgraded Graphic Packaging (GPK) to Overweight with an $11.50 target. RBC upgraded Lakefront Biotherapeutics (LKFT) to Outperform with a $45 target. Guggenheim upgraded Editas Medicine (EDIT) to Buy with a $5 target. Wedbush downgraded Compass Therapeutics (CMPX) to Neutral with a $1 target.

Related tickers